AU2001253495A1 - Treating graft rejection with ccr5 inhibitors - Google Patents

Treating graft rejection with ccr5 inhibitors

Info

Publication number
AU2001253495A1
AU2001253495A1 AU2001253495A AU5349501A AU2001253495A1 AU 2001253495 A1 AU2001253495 A1 AU 2001253495A1 AU 2001253495 A AU2001253495 A AU 2001253495A AU 5349501 A AU5349501 A AU 5349501A AU 2001253495 A1 AU2001253495 A1 AU 2001253495A1
Authority
AU
Australia
Prior art keywords
graft rejection
ccr5 inhibitors
treating graft
treating
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253495A
Inventor
Wayne W. Hancock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2001253495A1 publication Critical patent/AU2001253495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001253495A 2000-04-14 2001-04-13 Treating graft rejection with ccr5 inhibitors Abandoned AU2001253495A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54962500A 2000-04-14 2000-04-14
US09549625 2000-04-14
PCT/US2001/012206 WO2001078707A1 (en) 2000-04-14 2001-04-13 Treating graft rejection with ccr5 inhibitors

Publications (1)

Publication Number Publication Date
AU2001253495A1 true AU2001253495A1 (en) 2001-10-30

Family

ID=24193784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253495A Abandoned AU2001253495A1 (en) 2000-04-14 2001-04-13 Treating graft rejection with ccr5 inhibitors

Country Status (3)

Country Link
US (1) US20020019345A1 (en)
AU (1) AU2001253495A1 (en)
WO (1) WO2001078707A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
US20020160947A1 (en) * 2001-04-03 2002-10-31 Millennium Pharmaceuticals, Inc. Synergistic method for prolonging allograft survival
CA2472682A1 (en) * 2002-01-22 2003-07-31 Merck & Co., Inc. Treating stress response with chemokine receptor ccr5 modulators
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
AU2003266152A1 (en) * 2002-09-13 2004-04-30 University Of Maryland Biotechnology COMPOSITIONS FOR INDUCING INCREASED LEVELS OF Beta-CHEMOKINES AND METHODS OF USE THEREFOR
US7091211B2 (en) 2003-07-31 2006-08-15 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
CN101918451A (en) * 2008-01-15 2010-12-15 弗·哈夫曼-拉罗切有限公司 Afucosylated antibody of anti-CCR5 and uses thereof
EP3107564A4 (en) * 2014-02-18 2017-08-30 CytoDyn Inc. Use of anti-ccr5 antibodies in graft versus host disease
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
CA3045296A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
US20020019345A1 (en) 2002-02-14
WO2001078707A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2002228435A1 (en) Graft rejection inhibitors
AU2001253496A1 (en) Treating graft rejection with cxcr3 inhibitors
AU2002230661A1 (en) Implantable vascular graft
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001264898A1 (en) Ureteral stent
AUPQ610700A0 (en) Automatic table game
AU2001288720A1 (en) Implantable article
AU4882101A (en) Mmp-12 inhibitors
AU2001231104A1 (en) Methods for treating diabetes
AU2001243535A1 (en) Paraffin bath
ZA200106160B (en) Compositions and methods for treating cataracts.
AU2001253495A1 (en) Treating graft rejection with ccr5 inhibitors
AU2001235988A1 (en) Solenoid
AU2001279850A1 (en) Method and arrangement for studsystem
AU5841600A (en) Jewelry piece set
AU2001259198A1 (en) Stent graft assembly and method
AUPR150700A0 (en) Automated music arranger
AU2001296709A1 (en) Gemstone
AU2002367184A1 (en) Solenoid
AU2001236718A1 (en) Bioreactor and related method
AU2001271400A1 (en) Bioelastomer nanomachines and biosensors
AU2002222628A1 (en) Keratinocyte proliferation inhibitors
EP1298216A4 (en) Process for treating with enzyme
AU2002216930A1 (en) System for treating vascular adhesions
AU2001243297A1 (en) Method for treating or preventing depression